MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
06 nov. 2024 16h05 HE
|
MaxCyte, Inc.
ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development,...
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
06 août 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
07 mai 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 7, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused...
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
12 mars 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
04 mars 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD, March 4, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
08 janv. 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD, January 8, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
08 nov. 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD, November 8, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte to Participate in Two Upcoming Investor Conferences
06 nov. 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD, November 6, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling...
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
04 oct. 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD, October 4, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
09 août 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD, August 9, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...